Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A study in Nature describes a single-cell-type strategy for vascular cell therapies that involves the artificial transplantation of mitochondria to endothelial cells, which promotes mitophagy and facilitates the formation of functional vessels in ischaemic tissue without the need for mesenchymal stromal cell support.
Activation of the bile acid receptor TGR5 inhibits CD36-mediated fatty acid uptake in cardiomyocytes and protects against cardiac lipotoxicity and the development of diabetic cardiomyopathy in mice, according to a new study.
In the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.
Treatment for periodontal disease might reduce the recurrence of atrial fibrillation (AF) in patients undergoing ablation, suggesting that periodontitis is a modifiable risk factor for AF.
Findings from the ORBITA-COSMIC trial show that treatment of patients with stable coronary artery disease using a coronary sinus reducer improves angina symptoms but does not increase transmural myocardial perfusion.
According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.
Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone.
Three randomized clinical trials presented at ACC.24 demonstrate that olezarsen and plozasiran, RNA-based therapies that target APOC3, can robustly reduce plasma triglyceride levels in patients with moderate to severe hypertriglyceridaemia.
The under-representation of women in cardiovascular clinical trials persists across participant, clinician and research roles. This gap perpetuates health inequity and hampers the generation, translation and implementation of optimal evidence-based care. Urgent action is needed to address barriers, promote diversity, and ensure inclusive trial design and health-care delivery and dissemination, for more equitable cardiovascular health.
In the REDUCE-AMI trial, the use of β-blockers in patients with acute myocardial infarction (MI) who have undergone early coronary angiography and have a preserved left ventricular ejection fraction did not reduce the risk of death or new MI compared with no β-blocker use.
In patients with symptomatic aortic stenosis and a small aortic annulus, a self-expanding valve has similar rates of clinical outcomes at 1 year and lower rates of bioprosthetic dysfunction compared with a balloon-expandable valve.
After myocardial infarction, the heart secretes small extracellular vesicles with pro-neoplastic properties that can accelerate tumour growth when taken up by cancer cells.
In ST-segment elevation myocardial infarction, the role of interventional modification of thrombi in the coronary arteries before stenting is controversial. However, innovations in stroke intervention have sparked renewed interest in thrombus modification approaches. We discuss current and emerging techniques to extract or disperse thrombi, aiming to reduce downstream embolization, microvascular obstruction and myocardial injury.
A new study identifies a hormone that is secreted by the gut in response to cholesterol absorption and can inhibit cholesterol synthesis in the liver, which prevents an increase in circulating cholesterol levels.
In patients with carotid artery disease, the presence of microplastics and nanoplastics in the carotid plaque is associated with an increased risk of death or major cardiovascular events compared with patients in whom microplastics and nanoplastics were not detected.
In this Tools of the Trade article, Trivett discusses the potential of long-read sequencing in generating high-quality reference genomes of animal models of cardiovascular disease.